Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

AMNEAL PHARMACEUTICALS, INC. (AMRX) vs Liquidia Corporation (LQDA)

AMNEAL PHARMACEUTICALS, INC. and Liquidia Corporation are both Drug Manufacturers Specialty & Generic companies. AMNEAL PHARMACEUTICALS, INC. and Liquidia Corporation are of similar size ($6.4B and $6.3B). AMNEAL PHARMACEUTICALS, INC. trades at the lower P/E: 39.5× against 43.6×. Liquidia Corporation grew revenue faster over the last twelve months: 2,233.7% against 9.28%. Liquidia Corporation has the higher net margin (30.7% vs 5.05%) and the higher return on invested capital (121.1% vs 11.1%). Across the 21 metrics below, Liquidia Corporation leads on 15 and AMNEAL PHARMACEUTICALS, INC. on 6.

Valuation

Metric AMRX LQDA Drug Manufacturers Specialty & Generic median
P/E 39.54 43.59 20.14
P/S 2.02 13.49 2.25
P/B 191.09 31.17 1.90
Price to free cash flow n/m 40.36 16.54
EV/EBITDA 13.30 35.09 12.29
EV/Sales 2.84 13.25 2.56
Earnings yield 2.53% 2.29% (2.99%)
Free cash flow yield (0.18%) 2.48% 0.00%

Profitability

Metric AMRX LQDA Drug Manufacturers Specialty & Generic median
Gross margin 39.32% 92.54% 53.94%
Operating margin 14.56% 37.39% 0.00%
Net margin 5.05% 30.74% 0.00%
Free cash flow margin (0.37%) 33.42% 0.00%
Return on equity (395.84%) 131.82% (0.40%)
Return on assets 4.37% 35.57% (3.32%)
Return on invested capital 11.05% 121.05% 0.00%

Growth

Metric AMRX LQDA Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 9.28% 2,233.65% 10.01%
EPS growth (last fiscal year) 157.89% 51.81% —
Revenue growth, 5-year CAGR 8.66% 65.24% 6.74%
Net income growth, 5-year CAGR (4.57%) 0.00% 0.00%

Health

Metric AMRX LQDA Drug Manufacturers Specialty & Generic median
Debt to equity 80.86 0.90 0.05
Current ratio 2.20 2.31 2.31
Net debt to EBITDA 3.62 (0.01) 0.85

Dividend

Metric AMRX LQDA Drug Manufacturers Specialty & Generic median
Dividend yield 0.27% — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric AMRX LQDA Drug Manufacturers Specialty & Generic median
Market cap 6.32b 6.36b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack